Market Research Report: Global GITR (TNFRSF18) Agonist Therapeutics Market
Report Overview
This report provides a strategic analysis of the global market for therapeutic agents targeting the Tumor Necrosis Factor Receptor Superfamily Member 18 (TNFRSF18), commonly known as Glucocorticoid-Induced TNFR-Related Protein (GITR). The market encompasses monoclonal antibodies, fusion proteins, and other biologic modulators in clinical development, aimed at treating cancer and autoimmune diseases by modulating immune cell activity.
Executive Summary
The global GITR (TNFRSF18) agonist therapeutics market is in a pivotal clinical development phase, with an estimated pipeline valuation of USD XX million in 2025. It is projected to reach USD YY million by 2036, growing at a compound annual growth rate (CAGR) of ZZ% during the forecast period (2026-2036). This anticipated growth is contingent upon successful late-stage clinical trial results, regulatory approvals, and the integration of GITR-targeting agents into combination immuno-oncology regimens.
Market Segmentation Analysis
1. By Drug Type (Mechanism of Action):
-
Agonistic Monoclonal Antibodies (mAbs): The dominant modality, designed to activate GITR signaling on effector T cells and regulatory T cells (Tregs).
-
GITR Ligand (GITRL) Fusion Proteins: Recombinant proteins aiming to stimulate the receptor via its natural ligand.
-
Bispecific & Multifunctional Molecules: Agents combining GITR targeting with other immune-modulatory functions (e.g., PD-1 inhibition, T-cell engagers).
2. By Target Indication:
-
Oncology (Primary Application):
-
Solid Tumors: Melanoma, Non-Small Cell Lung Carcinoma (NSCLC), Gastric/Gastroesophageal Junction Cancer, Head and Neck Cancers.
-
Hematological Malignancies: Lymphoma, Leukemia.
-
-
Autoimmune & Inflammatory Diseases: (Exploratory applications) Rheumatoid arthritis, inflammatory bowel disease.
3. By Development Phase:
-
Preclinical/Discovery
-
Phase I Clinical Trials
-
Phase II Clinical Trials (Most active segment)
-
Phase III Clinical Trials & Regulatory Review (Future pivotal segment)
-
Post-Marketing (Commercial)
4. By Therapeutic Approach:
-
Monotherapy
-
Combination Therapy: In combination with PD-1/PD-L1 inhibitors, chemotherapy, radiation, or other immunotherapies.
Regional Analysis
-
North America: Leading market, driven by the U.S.'s dominant biotechnology sector, high concentration of clinical trial sites, favorable FDA regulatory frameworks for oncology drugs, and significant venture capital investment.
-
Europe: Major market with strong academic immunology research and active pharmaceutical company pipelines in Germany, the UK, and Switzerland. EMA's adaptive pathways support development.
-
Asia-Pacific: Emerging as a critical region for patient recruitment in global clinical trials, with growing biotech capabilities in China, Japan, and Australia. Japan's PMDA shows increasing engagement with novel immuno-oncology targets.
-
Rest of the World: Limited direct market in early stages, but participation in multi-regional clinical trials is increasing in select countries.
Competitive Landscape & Key Players
The landscape is defined by innovative biotech and large pharmaceutical companies with deep immuno-oncology pipelines.
-
Bristol-Myers Squibb Company (via acquisition of Celgene, pipeline includes lirilumab-related combinations)
-
Merck & Co., Inc. (Keytruda combinations with GITR agonists)
-
Novartis AG
-
Amgen Inc.
-
Regeneron Pharmaceuticals, Inc.
-
AstraZeneca/MedImmune LLC
-
Incyte Corporation
-
OncoMed Pharmaceuticals, Inc. (now Mereo BioPharma)
-
Agenus Inc. (Incognate platform, AGEN1571)
-
TG Therapeutics, Inc.
-
Other Notable Innovators: Ablynx NV (now Sanofi), Apogenix GmbH, Five Prime Therapeutics, Inc. (now Amgen), TRIGR Therapeutics, Phio Pharmaceuticals Corp.
Strategic Analysis Frameworks
Porter’s Five Forces Analysis
-
Competitive Rivalry: High (in R&D phase). Intense competition among biopharma to achieve clinical proof-of-concept first and secure dominant intellectual property. Success will shift rivalry to commercialization against established immunotherapies.
-
Bargaining Power of Suppliers: Low to Moderate. Suppliers include CROs and CDMOs, which are specialized but numerous. Unique platform technologies (e.g., specific antibody engineering) can grant suppliers moderate power.
-
Bargaining Power of Buyers: Potentially High (Future). Upon approval, buyers (hospitals, payers) will have significant power, comparing efficacy, safety, and cost against other immunotherapies in crowded oncology markets.
-
Threat of New Entrants: Moderate. High scientific and capital barriers exist. However, new entrants with novel biologic engineering platforms (e.g., nanobodies, bispecifics) can still enter the early-stage pipeline.
-
Threat of Substitutes: Very High. Direct substitutes include other T-cell co-stimulatory targets (OX40, 4-1BB, ICOS), established checkpoint inhibitors (PD-1, CTLA-4), cell therapies (CAR-T), and other novel immunomodulators.
SWOT Analysis
-
Strengths: Strong scientific rationale for enhancing anti-tumor immunity and depleting intratumoral Tregs; potential for synergistic combination with checkpoint blockade.
-
Weaknesses: Unproven clinical efficacy in late-stage trials; potential for immune-related adverse events (irAEs); complex biology with potential dual agonist/regulatory effects.
-
Opportunities: Address significant unmet need in checkpoint inhibitor-resistant cancers; first-to-market advantage in a novel mechanism class; expansion into autoimmune diseases.
-
Threats: Clinical trial failures leading to pipeline attrition; dominance of established PD-1 inhibitors; challenges in identifying predictive biomarkers for patient selection.
Trend Analysis
-
Focus on Rational Combinations: Development is predominantly in combination with anti-PD-1 therapy, based on strong preclinical synergy.
-
Biomarker-Driven Development: Increasing effort to identify biomarkers (e.g., tumor GITR expression, Treg infiltration) to select patients most likely to respond.
-
Next-Generation Engineering: Shift towards bispecific molecules (e.g., GITR x PD-1) and conditionally active biologics (Probody® therapeutics) to enhance tumor specificity and safety.
-
Exploration Beyond Oncology: Early preclinical and clinical investigation in autoimmune disorders, leveraging GITR's role in Treg function.
Market Drivers & Challenges
-
Drivers:
-
High unmet need for effective therapies in patients resistant to PD-1/PD-L1 inhibitors.
-
Robust investment in immuno-oncology R&D.
-
Encouraging early-phase clinical data generating proof-of-concept.
-
Favorable regulatory designations (e.g., Fast Track, Orphan Drug) accelerating development.
-
-
Challenges:
-
Clinical Efficacy Hurdle: Demonstrating significant overall survival benefit in randomized trials.
-
Safety & Toxicity Profile: Managing potential on-target, off-tumor toxicity and irAEs.
-
High Development Costs & Risk: Significant capital required for late-stage trials with high failure rates.
-
Market Access & Reimbursement: Future challenges in proving cost-effectiveness in a competitive landscape.
-
Value Chain Analysis
-
Basic Research & Target Validation: Academic and biotech discovery of GITR biology and therapeutic hypothesis.
-
Biologic Drug Discovery & Preclinical Development: Antibody generation, engineering, in vitro/vivo pharmacology and toxicology studies.
-
Clinical Development & Trials: Phased clinical trials (I-III) conducted globally to establish safety and efficacy.
-
Regulatory Affairs & Approval: Navigating FDA, EMA, and other health authority interactions for marketing authorization.
-
Commercial Manufacturing: Scaling up GMP production of biologic drugs, often via partnerships with CDMOs.
-
Commercialization & Market Access: Launch, marketing to oncologists, pricing negotiations, and securing reimbursement.
-
Post-Marketing Surveillance & Lifecycle Management: Phase IV studies and exploring new indications or combinations.
Quick Recommendations for Stakeholders
-
For Biotechnology Companies (Developers): Prioritize robust biomarker strategies from Phase I to identify responsive patient populations. Seek strategic partnerships with large pharma possessing complementary assets (e.g., anti-PD-1 drugs) and commercial infrastructure. Design trials with clear, registrational endpoints.
-
For Large Pharmaceutical Companies: Actively in-license or acquire promising GITR programs with strong mechanistic data and intelligent clinical trial designs. Integrate these assets into existing immuno-oncology combination portfolios to create synergistic treatment regimens.
-
For Investors: Conduct deep due diligence on the biological rationale, clinical trial design, and management team of developers. Focus on companies with differentiated molecule engineering (e.g., improved Fc function, bispecifics), clear biomarker strategies, and strong partnership potential. Diversify across the co-stimulatory target class.
-
For Research Institutions: Continue fundamental research into GITR signaling biology in different disease contexts and immune cell subsets. Collaborate with industry on translational studies to bridge discovery and clinical application.
-
For Regulatory Agencies: Engage early with sponsors via pre-IND meetings to guide development pathways for this novel class. Consider adaptive trial designs and surrogate endpoints to efficiently evaluate efficacy while ensuring patient safety.
Table of Contents
Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Research Report 2026
1 Industry Overview of Tumor Necrosis Factor Receptor Superfamily Member 18
1.1 Definition and Specifications of Tumor Necrosis Factor Receptor Superfamily Member 18
1.1.1 Definition of Tumor Necrosis Factor Receptor Superfamily Member 18
1.1.2 Specifications of Tumor Necrosis Factor Receptor Superfamily Member 18
1.2 Classification of Tumor Necrosis Factor Receptor Superfamily Member 18
1.2.1 AMG-228
1.2.2 BMS-986156
1.2.3 FPA-154
1.2.4 GWN-323
1.2.5 INCAGN-1876
1.2.6 Others
1.3 Applications of Tumor Necrosis Factor Receptor Superfamily Member 18
1.3.1 Melanoma
1.3.2 Non-Small Cell Lung Cancer
1.3.3 Gastric Cancer
1.3.4 Blood Cancer
1.3.5 Others
1.4 Market Segment by Regions
1.4.1 North America
1.4.2 Europe
1.4.3 China
1.4.4 Japan
1.4.5 Southeast Asia
1.4.6 India
2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
2.3 Manufacturing Process Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
2.4 Industry Chain Structure of Tumor Necrosis Factor Receptor Superfamily Member 18
3 Technical Data and Manufacturing Plants Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
3.1 Capacity and Commercial Production Date of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
3.2 Manufacturing Plants Distribution of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
3.3 R&D Status and Technology Source of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
3.4 Raw Materials Sources Analysis of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
4 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Overall Market Overview
4.1 E Overall Market Analysis
4.2 Capacity Analysis
4.2.1 E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Capacity and Growth Rate Analysis
4.2.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Capacity Analysis (Company Segment)
4.3 Sales Analysis
4.3.1 E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales and Growth Rate Analysis
4.3.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Analysis (Company Segment)
4.4 Sales Price Analysis
4.4.1 E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price
4.4.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis (Company Segment)
5 Tumor Necrosis Factor Receptor Superfamily Member 18 Regional Market Analysis
5.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.1.1 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.1.2 North America E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.1.3 North America E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.1.4 North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
5.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.2.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.2.2 Europe E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.2.3 Europe E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.2.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
5.3 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.3.1 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.3.2 China E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.3.3 China E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.3.4 China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
5.4 Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.4.1 Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.4.2 Japan E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.4.3 Japan E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.4.4 Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
5.5 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.5.1 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.5.2 Southeast Asia E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.5.3 Southeast Asia E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.5.4 Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
5.6 India Tumor Necrosis Factor Receptor Superfamily Member 18 Market Analysis
5.6.1 India Tumor Necrosis Factor Receptor Superfamily Member 18 Market Overview
5.6.2 India E Tumor Necrosis Factor Receptor Superfamily Member 18 Local Supply, Import, Export, Local Consumption Analysis
5.6.3 India E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Analysis
5.6.4 India Tumor Necrosis Factor Receptor Superfamily Member 18 Market Share Analysis
6 Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Segment Market Analysis (by Type)
6.1 Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales by Type
6.2 Different Types of Tumor Necrosis Factor Receptor Superfamily Member 18 Product Interview Price Analysis
6.3 Different Types of Tumor Necrosis Factor Receptor Superfamily Member 18 Product Driving Factors Analysis
6.3.1 AMG-228 Growth Driving Factor Analysis
6.3.2 BMS-986156 Growth Driving Factor Analysis
6.3.3 FPA-154 Growth Driving Factor Analysis
6.3.4 GWN-323 Growth Driving Factor Analysis
6.3.5 INCAGN-1876 Growth Driving Factor Analysis
6.3.6 Others Growth Driving Factor Analysis
7 Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Segment Market Analysis (by Application)
7.1 Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption by Application
7.2 Different Application of Tumor Necrosis Factor Receptor Superfamily Member 18 Product Interview Price Analysis
7.3 Different Application of Tumor Necrosis Factor Receptor Superfamily Member 18 Product Driving Factors Analysis
7.3.1 Melanoma of Tumor Necrosis Factor Receptor Superfamily Member 18 Growth Driving Factor Analysis
7.3.2 Non-Small Cell Lung Cancer of Tumor Necrosis Factor Receptor Superfamily Member 18 Growth Driving Factor Analysis
7.3.3 Gastric Cancer of Tumor Necrosis Factor Receptor Superfamily Member 18 Growth Driving Factor Analysis
7.3.4 Blood Cancer of Tumor Necrosis Factor Receptor Superfamily Member 18 Growth Driving Factor Analysis
7.3.5 Others of Tumor Necrosis Factor Receptor Superfamily Member 18 Growth Driving Factor Analysis
8 Major Manufacturers Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
8.1 Ablynx NV
8.1.1 Company Profile
8.1.2 Product Picture and Specifications
8.1.2.1 Product A
8.1.2.2 Product B
8.1.3 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.1.4 Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.2 Amgen Inc
8.2.1 Company Profile
8.2.2 Product Picture and Specifications
8.2.2.1 Product A
8.2.2.2 Product B
8.2.3 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.2.4 Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.3 Apogenix GmbH
8.3.1 Company Profile
8.3.2 Product Picture and Specifications
8.3.2.1 Product A
8.3.2.2 Product B
8.3.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.3.4 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.4 Bristol-Myers Squibb Company
8.4.1 Company Profile
8.4.2 Product Picture and Specifications
8.4.2.1 Product A
8.4.2.2 Product B
8.4.3 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.4.4 Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.5 Five Prime Therapeutics Inc
8.5.1 Company Profile
8.5.2 Product Picture and Specifications
8.5.2.1 Product A
8.5.2.2 Product B
8.5.3 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.5.4 Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.6 Incyte Corp
8.6.1 Company Profile
8.6.2 Product Picture and Specifications
8.6.2.1 Product A
8.6.2.2 Product B
8.6.3 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.6.4 Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.7 MedImmune LLC
8.7.1 Company Profile
8.7.2 Product Picture and Specifications
8.7.2.1 Product A
8.7.2.2 Product B
8.7.3 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.7.4 MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.8 Merck & Co Inc
8.8.1 Company Profile
8.8.2 Product Picture and Specifications
8.8.2.1 Product A
8.8.2.2 Product B
8.8.3 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.8.4 Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.9 Novartis AG
8.9.1 Company Profile
8.9.2 Product Picture and Specifications
8.9.2.1 Product A
8.9.2.2 Product B
8.9.3 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.9.4 Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.10 OncoMed Pharmaceuticals Inc
8.10.1 Company Profile
8.10.2 Product Picture and Specifications
8.10.2.1 Product A
8.10.2.2 Product B
8.10.3 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Sales, Ex-factory Price, Revenue, Gross Margin Analysis
8.10.4 OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution Analysis
8.11 Regeneron Pharmaceuticals Inc
9 Development Trend of Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18 Market
9.1 Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trend Analysis
9.1.1 Global 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Volume and Value) Forecast
9.1.2 Global 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price Forecast
9.2 Tumor Necrosis Factor Receptor Superfamily Member 18 Regional Market Trend
9.2.1 North America 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.2.2 Europe 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.2.3 China 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.2.4 Japan 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.2.5 Southeast Asia 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.2.6 India 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Forecast
9.3 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trend (Product Type)
9.4 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Trend (Application)
10 Tumor Necrosis Factor Receptor Superfamily Member 18 Marketing Type Analysis
10.1 Tumor Necrosis Factor Receptor Superfamily Member 18 Regional Marketing Type Analysis
10.2 Tumor Necrosis Factor Receptor Superfamily Member 18 International Trade Type Analysis
10.3 Traders or Distributors with Contact Information of Tumor Necrosis Factor Receptor Superfamily Member 18 by Region
10.4 Tumor Necrosis Factor Receptor Superfamily Member 18 Supply Chain Analysis
11 Consumers Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
11.1 Consumer 1 Analysis
11.2 Consumer 2 Analysis
11.3 Consumer 3 Analysis
11.4 Consumer 4 Analysis
12 Conclusion of the Global Tumor Necrosis Factor Receptor Superfamily Member 18 Market Professional Survey Report
Methodology
Analyst Introduction
Data Source
List of Tables and Figures
Figure Picture of Tumor Necrosis Factor Receptor Superfamily Member 18
Table Product Specifications of Tumor Necrosis Factor Receptor Superfamily Member 18
Table Classification of Tumor Necrosis Factor Receptor Superfamily Member 18
Figure Global Production Market Share of Tumor Necrosis Factor Receptor Superfamily Member 18 by Type in
Figure AMG-228 Picture
Table Major Manufacturers of AMG-228
Figure BMS-986156 Picture
Table Major Manufacturers of BMS-986156
Figure FPA-154 Picture
Table Major Manufacturers of FPA-154
Figure GWN-323 Picture
Table Major Manufacturers of GWN-323
Figure INCAGN-1876 Picture
Table Major Manufacturers of INCAGN-1876
Figure Others Picture
Table Major Manufacturers of Others
Table Applications of Tumor Necrosis Factor Receptor Superfamily Member 18
Figure Global Consumption Volume Market Share of Tumor Necrosis Factor Receptor Superfamily Member 18 by Application in
Figure Melanoma Examples
Table Major Consumers in Melanoma
Figure Non-Small Cell Lung Cancer Examples
Table Major Consumers in Non-Small Cell Lung Cancer
Figure Gastric Cancer Examples
Table Major Consumers in Gastric Cancer
Figure Blood Cancer Examples
Table Major Consumers in Blood Cancer
Figure Others Examples
Table Major Consumers in Others
Figure Market Share of Tumor Necrosis Factor Receptor Superfamily Member 18 by Regions
Figure North America Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Figure Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Figure China Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Figure Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Figure Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Figure India Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) (2013-2025)
Table Tumor Necrosis Factor Receptor Superfamily Member 18 Raw Material and Suppliers
Table Manufacturing Cost Structure Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18 in
Figure Manufacturing Process Analysis of Tumor Necrosis Factor Receptor Superfamily Member 18
Figure Industry Chain Structure of Tumor Necrosis Factor Receptor Superfamily Member 18
Table Capacity and Commercial Production Date of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
Table Manufacturing Plants Distribution of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
Table R&D Status and Technology Source of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
Table Raw Materials Sources Analysis of Global Tumor Necrosis Factor Receptor Superfamily Member 18 Major Manufacturers
Table Global Capacity, Sales , Price, Cost, Sales Revenue (M USD) and Gross Margin of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Volume) and Growth Rate
Figure Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Value) and Growth Rate
Table E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Capacity and Growth Rate
Table Global Tumor Necrosis Factor Receptor Superfamily Member 18 Capacity (K Pcs) List (Company Segment)
Table E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs) and Growth Rate
Table Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs) List (Company Segment)
Table E Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Table Global Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs) List (Company Segment)
Figure North America Capacity Overview
Table North America Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure North America E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure North America Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Figure Europe Capacity Overview
Table Europe Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure Europe E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure Europe Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Figure China Capacity Overview
Table China Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure China E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure China Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Figure Japan Capacity Overview
Table Japan Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure Japan E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure Japan Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Figure Southeast Asia Capacity Overview
Table Southeast Asia Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure Southeast Asia E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Figure India Capacity Overview
Table India Supply, Import, Export and Consumption (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 E
Figure India E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs)
Figure India Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Market Share
Table Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs) by Type
Table Different Types Tumor Necrosis Factor Receptor Superfamily Member 18 Product Interview Price
Table Global E Tumor Necrosis Factor Receptor Superfamily Member 18 Sales (K Pcs) by Application
Table Different Application Tumor Necrosis Factor Receptor Superfamily Member 18 Product Interview Price
Table Ablynx NV Information List
Table Product Overview
Table Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Ablynx NV Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Amgen Inc Information List
Table Product Overview
Table Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Amgen Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Apogenix GmbH Information List
Table Product Overview
Table Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Bristol-Myers Squibb Company Information List
Table Product Overview
Table Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Bristol-Myers Squibb Company Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Five Prime Therapeutics Inc Information List
Table Product Overview
Table Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Five Prime Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Incyte Corp Information List
Table Product Overview
Table Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Incyte Corp Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table MedImmune LLC Information List
Table Product Overview
Table MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure MedImmune LLC Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Merck & Co Inc Information List
Table Product Overview
Table Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Merck & Co Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Novartis AG Information List
Table Product Overview
Table Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure Novartis AG Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table OncoMed Pharmaceuticals Inc Information List
Table Product Overview
Table OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Revenue (Million USD), Sales (K Pcs), Ex-factory Price (USD/Pcs)
Figure OncoMed Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 18 Business Region Distribution
Table Regeneron Pharmaceuticals Inc Information List
Figure Global 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (K Pcs) and Growth Rate Forecast
Figure Global 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Market Size (Million USD) and Growth Rate Forecast
Figure Global 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Sales Price (USD/Pcs) Forecast
Figure North America 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure China 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Europe 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Southeast Asia 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure Japan 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Figure India 2018-2025 Tumor Necrosis Factor Receptor Superfamily Member 18 Consumption Volume (K Pcs) and Growth Rate Forecast
Table Global Sales Volume (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 by Type 2018-2025
Table Global Consumption Volume (K Pcs) of Tumor Necrosis Factor Receptor Superfamily Member 18 by Application 2018-2025
Table Traders or Distributors with Contact Information of Tumor Necrosis Factor Receptor Superfamily Member 18 by Region
Market Segmentation Analysis
1. By Drug Type (Mechanism of Action):
-
Agonistic Monoclonal Antibodies (mAbs): The dominant modality, designed to activate GITR signaling on effector T cells and regulatory T cells (Tregs).
-
GITR Ligand (GITRL) Fusion Proteins: Recombinant proteins aiming to stimulate the receptor via its natural ligand.
-
Bispecific & Multifunctional Molecules: Agents combining GITR targeting with other immune-modulatory functions (e.g., PD-1 inhibition, T-cell engagers).
2. By Target Indication:
-
Oncology (Primary Application):
-
Solid Tumors: Melanoma, Non-Small Cell Lung Carcinoma (NSCLC), Gastric/Gastroesophageal Junction Cancer, Head and Neck Cancers.
-
Hematological Malignancies: Lymphoma, Leukemia.
-
-
Autoimmune & Inflammatory Diseases: (Exploratory applications) Rheumatoid arthritis, inflammatory bowel disease.
3. By Development Phase:
-
Preclinical/Discovery
-
Phase I Clinical Trials
-
Phase II Clinical Trials (Most active segment)
-
Phase III Clinical Trials & Regulatory Review (Future pivotal segment)
-
Post-Marketing (Commercial)
4. By Therapeutic Approach:
-
Monotherapy
-
Combination Therapy: In combination with PD-1/PD-L1 inhibitors, chemotherapy, radiation, or other immunotherapies.
Regional Analysis
-
North America: Leading market, driven by the U.S.'s dominant biotechnology sector, high concentration of clinical trial sites, favorable FDA regulatory frameworks for oncology drugs, and significant venture capital investment.
-
Europe: Major market with strong academic immunology research and active pharmaceutical company pipelines in Germany, the UK, and Switzerland. EMA's adaptive pathways support development.
-
Asia-Pacific: Emerging as a critical region for patient recruitment in global clinical trials, with growing biotech capabilities in China, Japan, and Australia. Japan's PMDA shows increasing engagement with novel immuno-oncology targets.
-
Rest of the World: Limited direct market in early stages, but participation in multi-regional clinical trials is increasing in select countries.
Competitive Landscape & Key Players
The landscape is defined by innovative biotech and large pharmaceutical companies with deep immuno-oncology pipelines.
-
Bristol-Myers Squibb Company (via acquisition of Celgene, pipeline includes lirilumab-related combinations)
-
Merck & Co., Inc. (Keytruda combinations with GITR agonists)
-
Novartis AG
-
Amgen Inc.
-
Regeneron Pharmaceuticals, Inc.
-
AstraZeneca/MedImmune LLC
-
Incyte Corporation
-
OncoMed Pharmaceuticals, Inc. (now Mereo BioPharma)
-
Agenus Inc. (Incognate platform, AGEN1571)
-
TG Therapeutics, Inc.
